Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natural Killer T-Cells | 14 | 2025 | 77 | 2.600 |
Why?
|
| Neuroblastoma | 10 | 2025 | 511 | 1.100 |
Why?
|
| Interleukin-15 | 5 | 2025 | 95 | 0.870 |
Why?
|
| Galactosylceramides | 5 | 2018 | 15 | 0.860 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2025 | 790 | 0.760 |
Why?
|
| Lymphocyte Activation | 9 | 2023 | 690 | 0.690 |
Why?
|
| Adjuvants, Immunologic | 4 | 2012 | 359 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 1192 | 0.470 |
Why?
|
| Neoplasms | 3 | 2024 | 2755 | 0.440 |
Why?
|
| Glypicans | 2 | 2024 | 39 | 0.400 |
Why?
|
| Respiratory Mucosa | 1 | 2011 | 91 | 0.370 |
Why?
|
| HIV Antigens | 1 | 2009 | 12 | 0.330 |
Why?
|
| AIDS Vaccines | 1 | 2009 | 30 | 0.320 |
Why?
|
| Interleukins | 2 | 2020 | 116 | 0.310 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2023 | 262 | 0.300 |
Why?
|
| Gangliosides | 3 | 2025 | 64 | 0.250 |
Why?
|
| Nanoparticles | 2 | 2021 | 227 | 0.220 |
Why?
|
| Mice | 17 | 2023 | 17553 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 13 | 0.210 |
Why?
|
| Mice, Inbred NOD | 6 | 2023 | 285 | 0.210 |
Why?
|
| Cancer Vaccines | 2 | 2014 | 187 | 0.210 |
Why?
|
| Mice, SCID | 6 | 2023 | 571 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 674 | 0.190 |
Why?
|
| Administration, Intranasal | 3 | 2011 | 128 | 0.190 |
Why?
|
| Immunity, Mucosal | 3 | 2011 | 82 | 0.190 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 326 | 0.180 |
Why?
|
| L-Selectin | 2 | 2018 | 22 | 0.170 |
Why?
|
| Animals | 19 | 2023 | 33758 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 137 | 0.170 |
Why?
|
| Cytokines | 5 | 2024 | 1274 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2011 | 816 | 0.150 |
Why?
|
| Receptors, Antigen | 2 | 2016 | 34 | 0.150 |
Why?
|
| Contrast Media | 1 | 2021 | 452 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 147 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1680 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 428 | 0.130 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2313 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2014 | 41 | 0.120 |
Why?
|
| Vaccines, Attenuated | 1 | 2014 | 171 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 717 | 0.110 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2013 | 10 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2030 | 0.110 |
Why?
|
| Glycosphingolipids | 1 | 2012 | 12 | 0.100 |
Why?
|
| Interferon-gamma | 3 | 2010 | 509 | 0.100 |
Why?
|
| Humans | 18 | 2025 | 122439 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 390 | 0.100 |
Why?
|
| Macrophages | 2 | 2014 | 615 | 0.100 |
Why?
|
| Macaca mulatta | 2 | 2010 | 492 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 874 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 254 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 955 | 0.090 |
Why?
|
| Cell Separation | 1 | 2011 | 238 | 0.090 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 375 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 470 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2009 | 405 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 629 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2014 | 658 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1383 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2009 | 506 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2018 | 3083 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2009 | 148 | 0.080 |
Why?
|
| Cell Line | 2 | 2014 | 2791 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 3292 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1076 | 0.070 |
Why?
|
| Immunization | 1 | 2009 | 303 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2011 | 4363 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1118 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2007 | 55 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2009 | 668 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 981 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 480 | 0.070 |
Why?
|
| Vaccination | 1 | 2011 | 925 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2018 | 58 | 0.060 |
Why?
|
| HIV-1 | 1 | 2009 | 471 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2007 | 296 | 0.060 |
Why?
|
| Papillomavirus Vaccines | 1 | 2007 | 92 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 57 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 2 | 2016 | 120 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 903 | 0.060 |
Why?
|
| Female | 8 | 2024 | 64925 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2018 | 238 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 229 | 0.060 |
Why?
|
| Lung | 1 | 2011 | 1476 | 0.060 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2023 | 12 | 0.050 |
Why?
|
| Etanercept | 1 | 2023 | 39 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 30 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2007 | 749 | 0.050 |
Why?
|
| Apoptosis | 2 | 2020 | 1792 | 0.050 |
Why?
|
| Transduction, Genetic | 2 | 2014 | 297 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2440 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2007 | 812 | 0.050 |
Why?
|
| beta Catenin | 1 | 2023 | 208 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 76 | 0.050 |
Why?
|
| Radiometry | 1 | 2021 | 39 | 0.050 |
Why?
|
| Monocytes | 1 | 2023 | 359 | 0.050 |
Why?
|
| Vidarabine | 1 | 2020 | 79 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 231 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2023 | 332 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2014 | 398 | 0.040 |
Why?
|
| Immunity | 1 | 2020 | 183 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 207 | 0.040 |
Why?
|
| Granzymes | 1 | 2018 | 39 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 424 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 548 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 4651 | 0.030 |
Why?
|
| Child | 3 | 2023 | 24092 | 0.030 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 78 | 0.030 |
Why?
|
| Retroviridae | 1 | 2014 | 205 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 819 | 0.030 |
Why?
|
| Side-Population Cells | 1 | 2013 | 10 | 0.030 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2013 | 55 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 768 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 98 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 7 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 751 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2012 | 104 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 96 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 651 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 257 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 217 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 295 | 0.020 |
Why?
|
| Male | 3 | 2024 | 59583 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 542 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 1000 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 559 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 206 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 872 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 44 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2009 | 91 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 194 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 328 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 713 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 847 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 3769 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2007 | 19 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 461 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 2007 | 45 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 901 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 18787 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1526 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 839 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1933 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 25638 | 0.020 |
Why?
|
| Adult | 1 | 2024 | 28759 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4212 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2678 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3871 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4285 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12040 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 13806 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 18959 | 0.010 |
Why?
|